摘要
目的探讨阿立哌唑与利培酮对精神分裂症的疗效及安全性。方法选取80例精神分裂症患者,随机分为阿立哌唑组40例,利培酮组40例;分别给予阿立哌唑和利培酮治疗,疗程8周。在治疗前及治疗第1,2,4,6,8周末分别采用阳性和阴性症状量表(PANSS),治疗中出现的副反应采用症状量表(TESS)对两组进行评定。并于治疗前、中、后检查催乳素水平。结果两组治疗后PANSS评分均有显著下降。阿立哌唑组的锥体外系不良反应、体质量增加及月经失调均较利培酮组少而轻,且对催乳素水平没有影响。结论本研究结果表明,两药对精神分裂症均有较好疗效,起效快,不良反应小。
Objective To investigate the clinical efficacy and safety of aripiprazole and risperidone in treatment of the patients with acute schizophrenia.Methods Eighty patients of schizophrenia were randomly assigned into aripiprazole（n=40）and risperidone treatment groups（n=40）respectively for 8 weeks.Positive and negative syndrome scale（PANSS）and treatment emergent symptoms scale（TESS）were used before and at the end of 1,2,4,6 and 8 weeks of treatment for both groups.The plasma prolactin concentration was measured before,during and after treatment.Results The total scores of PANSS decreased significantly with treatment in both groups.Patients had less adverse events of extrapyramidal symptom,weight gain and abnormal menstruation cycle in aripiprazole group than those in risperidone group.There was no change in plasma prolactin concentration in both treatment groups.Conclusion Aripiprazole was as effective as risperidone in the treatment of patients with schizophrenia.Both of the medication had quick response in treatment and no severe adverse events observed.
出处
《中国预防医学杂志》
CAS
2010年第2期190-192,共3页
Chinese Preventive Medicine
